Literature DB >> 18256112

Forgiveness of non-adherence to HIV-1 antiretroviral therapy.

Jonathan Shuter1.   

Abstract

Superior adherence to HIV-1 antiretroviral therapy is a mainstay of successful HIV management. Studies performed in the early era of highly active antiretroviral therapy demonstrated the need for > or =95% adherence in order to achieve and sustain viral suppression. High rates of viral suppression have been observed at more moderate levels of adherence with newer antiretroviral regimens. The term 'forgiveness' is being used to describe the ability of a regimen to achieve and sustain viral suppression, despite suboptimal adherence. A variety of pharmacological, viral and host properties determine the level of forgiveness of any specific regimen. As the choice of treatment options continues to expand, forgiveness of non-adherence is likely to emerge as an increasingly important factor in therapeutic decision-making.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18256112     DOI: 10.1093/jac/dkn020

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  43 in total

1.  Depression at Treatment Initiation Predicts HIV Antiretroviral Adherence in Uganda.

Authors:  Glenn J Wagner; Mary Slaughter; Bonnie Ghosh-Dastidar
Journal:  J Int Assoc Provid AIDS Care       Date:  2016-11-30

2.  Challenges in initiating antiretroviral therapy in 2010.

Authors:  Cécile L Tremblay; Jean-Guy Baril; David Fletcher; Donald Kilby; Paul Macpherson; Stephen D Shafran; Mark W Tyndall
Journal:  Can J Infect Dis Med Microbiol       Date:  2010-08       Impact factor: 2.471

3.  Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa.

Authors:  Surulivelrajan Mallayasamy; Ayyappa Chaturvedula; Michael J Fossler; Mark Sale; Vineet Goti; Namandje N Bumpus; Mark A Marzinke; Craig W Hendrix; Jessica E Haberer
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

4.  Trends in ART Prescription and Viral Suppression Among HIV-Positive Young Adults in Care in the United States, 2009-2013.

Authors:  Linda Beer; Christine L Mattson; Heather Bradley; Roy L Shouse
Journal:  J Acquir Immune Defic Syndr       Date:  2017-09-01       Impact factor: 3.731

5.  [Compliance enhancement in drug therapy : opportunities and limitations].

Authors:  L Krolop; U Jaehde
Journal:  Internist (Berl)       Date:  2012-01       Impact factor: 0.743

6.  Factors associated with nonadherence to antiretroviral therapy in HIV-positive smokers.

Authors:  Rachel Marks King; Damon J Vidrine; Heather E Danysh; Faith E Fletcher; Sheryl McCurdy; Roberto C Arduino; Ellen R Gritz
Journal:  AIDS Patient Care STDS       Date:  2012-05-21       Impact factor: 5.078

7.  In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450.

Authors:  Tami Pilot-Matias; Rakesh Tripathi; Daniel Cohen; Isabelle Gaultier; Tatyana Dekhtyar; Liangjun Lu; Thomas Reisch; Michelle Irvin; Todd Hopkins; Ron Pithawalla; Timothy Middleton; Teresa Ng; Keith McDaniel; Yat Sun Or; Rajeev Menon; Dale Kempf; Akhteruzzaman Molla; Christine Collins
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

8.  Development and validation of a measure for intention to adhere to HIV treatment.

Authors:  Andrea Nelsen; Barbara W Trautner; Nancy J Petersen; Sunita Gupta; Maria Rodriguez-Barradas; Thomas P Giordano; Aanand D Naik
Journal:  AIDS Patient Care STDS       Date:  2012-06       Impact factor: 5.078

9.  Association between health literacy and HIV treatment adherence: further evidence from objectively measured medication adherence.

Authors:  Seth C Kalichman; Howard Pope; Denise White; Chauncey Cherry; Christina M Amaral; Connie Swetzes; Jody Flanagan; Moira O Kalichman
Journal:  J Int Assoc Physicians AIDS Care (Chic)       Date:  2008-12-04

10.  The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy.

Authors:  Michael Rosenblum; Steven G Deeks; Mark van der Laan; David R Bangsberg
Journal:  PLoS One       Date:  2009-09-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.